The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KZR | -23.17% | -89.32% | -36.04% | -97% |
| S&P | +16.9% | +95.99% | +14.39% | +147% |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.24M | 6.9% |
| Market Cap | $33.46M | -23.4% |
| Market Cap / Employee | $0.61M | 0.0% |
| Employees | 55 | -5.2% |
| Net Income | -$13.70M | 36.4% |
| EBITDA | -$14.36M | 33.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.37M | 21.5% |
| Accounts Receivable | $1.74M | 32.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.97M | -74.7% |
| Short Term Debt | $9.10M | 55.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.98% | -4.5% |
| Return On Invested Capital | -39.16% | -5.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.80M | 24.9% |
| Operating Free Cash Flow | -$12.80M | 24.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.42 | 0.37 | 0.30 | 0.32 | 25.67% |
| Price to Sales | 9.84 | 9.38 | 6.24 | - | |
| Price to Tangible Book Value | 3.74 | 0.37 | 0.30 | 0.32 | -87.43% |
| Enterprise Value to EBITDA | 3.46 | 3.14 | 3.72 | 3.85 | -18.98% |
| Return on Equity | -54.7% | -55.0% | -57.8% | -58.4% | 13.43% |
| Total Debt | $16.91M | $16.18M | $14.11M | $12.07M | -31.44% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
